Early research (Phase 1)Ended earlyNCT03240861
What this trial is testing
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer
Who this might be right for
HLA-A*0201 Positive Cells PresentLocally Advanced Malignant NeoplasmNY-ESO-1 Positive+2 more
Jonsson Comprehensive Cancer Center 5